DE102022103658A1 - Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer - Google Patents

Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer Download PDF

Info

Publication number
DE102022103658A1
DE102022103658A1 DE102022103658.8A DE102022103658A DE102022103658A1 DE 102022103658 A1 DE102022103658 A1 DE 102022103658A1 DE 102022103658 A DE102022103658 A DE 102022103658A DE 102022103658 A1 DE102022103658 A1 DE 102022103658A1
Authority
DE
Germany
Prior art keywords
tryptophan
hydroxytryptophan
composition according
peripheral degradation
peripheral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE102022103658.8A
Other languages
German (de)
English (en)
Inventor
gleich Anmelder Erfinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE102022103658.8A priority Critical patent/DE102022103658A1/de
Priority to PCT/EP2023/053129 priority patent/WO2023156275A1/en
Priority to CN202380022428.3A priority patent/CN118871096A/zh
Priority to AU2023222362A priority patent/AU2023222362A1/en
Priority to KR1020247030751A priority patent/KR20240152875A/ko
Priority to JP2024548458A priority patent/JP2025505294A/ja
Priority to EP23704337.7A priority patent/EP4479027A1/en
Priority to CA3243635A priority patent/CA3243635A1/en
Priority to US18/839,100 priority patent/US20250161270A1/en
Publication of DE102022103658A1 publication Critical patent/DE102022103658A1/de
Priority to MX2024009966A priority patent/MX2024009966A/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
DE102022103658.8A 2022-02-16 2022-02-16 Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer Pending DE102022103658A1 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE102022103658.8A DE102022103658A1 (de) 2022-02-16 2022-02-16 Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
JP2024548458A JP2025505294A (ja) 2022-02-16 2023-02-08 L-トリプトファン、l-5-ヒドロキシトリプトファンおよび末梢分解阻害剤を含む医薬組成物および医薬
CN202380022428.3A CN118871096A (zh) 2022-02-16 2023-02-08 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
AU2023222362A AU2023222362A1 (en) 2022-02-16 2023-02-08 Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
KR1020247030751A KR20240152875A (ko) 2022-02-16 2023-02-08 L-트립토판, l-5-하이드록시트립토판 및 말초 분해 억제제를 포함하는 약학 조성물 및 약제
PCT/EP2023/053129 WO2023156275A1 (en) 2022-02-16 2023-02-08 Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
EP23704337.7A EP4479027A1 (en) 2022-02-16 2023-02-08 Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
CA3243635A CA3243635A1 (en) 2022-02-16 2023-02-08 PHARMACEUTICAL COMPOSITION AND MEDICINE COMPRISING L-TRYPTOPHAN, L-5-HYDROXYTRYPTOPHAN AND A PERIPHERAL DEGRADATION INHIBITOR
US18/839,100 US20250161270A1 (en) 2022-02-16 2023-02-08 Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
MX2024009966A MX2024009966A (es) 2022-02-16 2024-08-14 Composicion farmaceutica y medicamento que comprenden l-triptofano, l-5-hidroxitriptofano y un inhibidor de la degradacion periferica

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102022103658.8A DE102022103658A1 (de) 2022-02-16 2022-02-16 Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer

Publications (1)

Publication Number Publication Date
DE102022103658A1 true DE102022103658A1 (de) 2023-08-17

Family

ID=85221827

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102022103658.8A Pending DE102022103658A1 (de) 2022-02-16 2022-02-16 Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer

Country Status (10)

Country Link
US (1) US20250161270A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479027A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025505294A (cg-RX-API-DMAC7.html)
KR (1) KR20240152875A (cg-RX-API-DMAC7.html)
CN (1) CN118871096A (cg-RX-API-DMAC7.html)
AU (1) AU2023222362A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243635A1 (cg-RX-API-DMAC7.html)
DE (1) DE102022103658A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009966A (cg-RX-API-DMAC7.html)
WO (1) WO2023156275A1 (cg-RX-API-DMAC7.html)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126672A (en) 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
DE3232873A1 (de) 1981-09-14 1983-03-31 F. Hoffmann-La Roche & Co AG, 4002 Basel Pharmazeutisches praeparat
WO1991007960A1 (fr) 1989-11-24 1991-06-13 Paul Trouillas Compositions pharmaceutiques destinees au traitement de l'ataxie et les troubles de l'equilibre
EP0344158B1 (de) 1986-12-13 1992-04-08 KAMPRAD, Joachim Schmerzpräparat
EP1784177B1 (de) 2004-08-12 2009-04-29 Dr. Kamprad Kg Formulierung für l-tryptophan mit carbidopa/ benserazid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
EP1751312A4 (en) * 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
US20060257469A1 (en) * 2005-04-05 2006-11-16 Bulka Yochanan R Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase
ES2948788T3 (es) * 2018-01-29 2023-09-19 Univ Duke Composiciones y métodos para mejorar la biodisponibilidad del 5-hidroxitriptófano

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126672A (en) 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
DE3232873A1 (de) 1981-09-14 1983-03-31 F. Hoffmann-La Roche & Co AG, 4002 Basel Pharmazeutisches praeparat
EP0344158B1 (de) 1986-12-13 1992-04-08 KAMPRAD, Joachim Schmerzpräparat
WO1991007960A1 (fr) 1989-11-24 1991-06-13 Paul Trouillas Compositions pharmaceutiques destinees au traitement de l'ataxie et les troubles de l'equilibre
EP1784177B1 (de) 2004-08-12 2009-04-29 Dr. Kamprad Kg Formulierung für l-tryptophan mit carbidopa/ benserazid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHAW, Kelly A.; TURNER, Jane; DEL MAR, Chris. Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database of Systematic Reviews, 2002, Nr. 1.
TURNER, Erick H.; BLACKWELL, Aaron D. 5-Hydroxytryptophan plus SSRIs for in-terferon-induced depression: synergistic mechanisms for normalizing synaptic seroto-nin. Medical hypotheses, 2005, 65. Jg., Nr. 1, S. 138-144.

Also Published As

Publication number Publication date
JP2025505294A (ja) 2025-02-21
WO2023156275A1 (en) 2023-08-24
CA3243635A1 (en) 2023-08-24
EP4479027A1 (en) 2024-12-25
AU2023222362A1 (en) 2024-09-12
CN118871096A (zh) 2024-10-29
KR20240152875A (ko) 2024-10-22
US20250161270A1 (en) 2025-05-22
MX2024009966A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
US20230240984A1 (en) Dimethyl sulfoxide (dmso) and methylsulfonylmethane (msm) formulations to treat osteoarthritis
EP0267321B1 (de) Ibuprofen enthaltendes Arzneimittel
JP4166951B2 (ja) 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ
JP2002518456A (ja) 脳血管の正常状態を支持するための栄養補助食品
JP2001513487A (ja) 糖尿病治療用組成物及び治療方法
Goole et al. Levodopa delivery systems for the treatment of Parkinson's disease: an overview
US5612061A (en) Composition and method for the treatment of premenstrual syndrome
JP2002518438A (ja) 不安状態または鬱病による神経および行動変化の予防および/または治療のための神経保護組成物
ZA200700395B (en) Novel formulation for L-tryptophane comprising carbidopa/benserazide
CN114786647B (zh) 口服药学立即释放组合物和用于重量减轻的治疗方法
JP2001518481A (ja) 経口投与のためのセロトニン含有製剤及びその使用方法
US4405629A (en) Process for increasing glycine levels in the brain and spinal cord
JPH0518811B2 (cg-RX-API-DMAC7.html)
WO1997038701A1 (en) Composition and method for the treatment of premenstrual syndrome
CN118871096A (zh) 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
White et al. Post-anaesthetic dental extraction analgesia: A comparison of paracetamol, codeine, caffeine (Solpadeine) and diflunisal (Dolobid)
DE202025107875U1 (de) Zusammensetzung, insbesondere zur Verwendung bei der Behandlung von Veisalgia
EP0344158A1 (de) Schmerzpräparat.
AU2015202432B2 (en) Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
BE894696A (fr) Nouveaux medicaments a base de 9,10-dihydro-ergonine pour le traitement de l'arteriosclerose

Legal Events

Date Code Title Description
R012 Request for examination validly filed